Drug Policy in the Czech Republic



The legal background of the current pharmaceutical pricing and reimbursement (P marketing authorization holders and insurance funds (IFs) also participate.


To present a general overview of the current Czech health care system and its PR principles.


The study used publicly available sources concerning health care, mainly acts related to public health care and public health care insurance, public notices related to PR setting, and statistical data.


Regulation covers P ∼€600,000 to €1.8 million) to enter the system. Products exceeding this budget impact have to negotiate risk-sharing schemes, mainly further discounts and/or budget caps.


The Czech pricing and reimbursement system is rather complex, taking into account clinical evidence, cost-effectiveness and budget impact. The strict regulations are a result of financial scarcity.


Jana Skoupá

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now